Jyseleca (Filgotinib)

Filgotinib selectively blocks Janus kinase 1 (JAK1), an enzyme that transmits signals from several pro‑inflammatory cytokines. By inhibiting JAK1, the drug reduces the transcription of inflammatory genes, leading to decreased activation of immune cells and lower levels of inflammation in joints and the colon.

The dosage of Jyseleca is determined by the prescribing physician based on the patient’s clinical condition, disease severity, and response to therapy. Healthcare professionals follow the approved prescribing information and adjust the regimen as needed for safety and efficacy.

Safety data for Filgotinib in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative options with their healthcare provider.

To request Jyseleca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Jyseleca (Filgotinib) is a selective JAK1 inhibitor, offering a more targeted approach compared with less selective JAK inhibitors such as tofacitinib, which affect multiple JAK isoforms. This selectivity may translate into a different safety profile, but clinical decisions should consider efficacy, patient history, and individual risk factors.

Jyseleca tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Jyseleca is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, preferably at the same time each day, unless otherwise directed by their prescriber. Food does not significantly affect its absorption.

The most serious risks include serious infections such as tuberculosis or opportunistic pathogens, venous thromboembolism, malignancies, and significant liver injury. Patients should be monitored regularly for signs of infection, changes in blood counts, liver function abnormalities, and any unexpected symptoms.

Jyseleca is contraindicated in patients with active serious infections, known hypersensitivity to Filgotinib, severe liver impairment, or a history of recurrent venous thromboembolism. Caution is also advised for individuals with uncontrolled cardiovascular disease, pregnancy, or breastfeeding until safety is established.